In a randomized, double-blind, placebo-controlled Phase 2 trial that evaluated 79 confirmed cases of COVID-19-infected subjects, SaNOtize’s early treatment for COVID-19 significantly reduced the level of SARS-CoV-2, including in patients with high viral loads. The average viral log reduction in the first 24 hours was 1.362, which corresponds to a decline of about 95% in viral replication. Within 72 hours, the SARS-CoV-2 viral load dropped by more than 99%. Most of these patients had been infected with the UK variant, considered a variant of concern.